Prazosin Should NOT Be Used for SVT
Prazosin is not indicated for the treatment of supraventricular tachycardia and may actually worsen the condition by causing reflex tachycardia. This alpha-1 blocker is an antihypertensive agent with no role in SVT management according to current guidelines.
Why Prazosin is Contraindicated
Mechanism of Harm
Prazosin's FDA label explicitly warns that it can cause "severe tachycardia with heart rates of 120-160 beats per minute" 1. This reflex tachycardia occurs as a compensatory response to the drug's vasodilatory effects and would be particularly dangerous in a patient already experiencing SVT, potentially:
- Worsening the existing tachyarrhythmia
- Increasing myocardial oxygen demand
- Precipitating hemodynamic instability
Additional Safety Concerns
The FDA label notes prazosin causes syncope in approximately 1% of patients, typically within 30-90 minutes of dosing, due to excessive postural hypotension 1. In an SVT patient who may already be experiencing hemodynamic compromise, this risk becomes unacceptable.
Evidence-Based SVT Treatment
Acute Management (Guideline-Recommended)
The 2019 ESC and 2015 ACC/AHA/HRS guidelines provide clear algorithmic treatment 2, 3:
First-line (Class I recommendations):
- Vagal maneuvers (modified Valsalva: 43% effective) 4
- IV adenosine (91% effective) - remains drug of choice 2, 3
- Synchronized cardioversion if hemodynamically unstable 3
Second-line for hemodynamically stable patients (Class IIa):
Long-Term Management
First-line (Class I):
- Catheter ablation (94.3-98.5% success rate) - most effective definitive therapy 4
- Oral beta-blockers, diltiazem, or verapamil for ongoing suppression 3
Alternative options (Class IIa-IIb):
- Flecainide or propafenone (in patients without structural heart disease) 3
Critical Pitfall to Avoid
Never use antihypertensive vasodilators like prazosin for rhythm control. The 2019 ESC guidelines consolidated and refined the list of appropriate antiarrhythmic drugs for SVT, and alpha-blockers have never been included 2. Prazosin's pharmacologic profile as a selective alpha-1 antagonist makes it fundamentally inappropriate for arrhythmia management 5.
If a patient with SVT is coincidentally taking prazosin for hypertension or PTSD, continue it for those indications but recognize it provides no antiarrhythmic benefit and may complicate acute SVT management.